Screening for colorectal cancer via a blood-based test may be as sensitive and specific as stool-based tests, according to the first prospective study to evaluate its accuracy in a screening population. The new blood-based test is reportedly able to detect circulating tumor DNA, which then can be analyzed for various characteristics, including cancer genetics and methylation.
The LUNAR-2 test from Guardant Health was 100% sensitive and 90% specific for detecting CRC in a multicenter Spanish